Unknown

Dataset Information

0

Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.


ABSTRACT: To facilitate the optimization of cancer immunotherapy lacking immune-related adverse events, we performed TCR repertoire analysis of tumor-infiltrating CD8+ T-cells in B16 melanoma-bearing mice receiving anti-PD-1, anti-CTLA-4, anti-4-1BB, anti-CD4 or a combination of anti-PD-1 and 4-1BB antibodies. Although CD8+ T-cells in the tumor were activated and expanded to a greater or lesser extent by these therapies, tumor growth suppression was achieved only by anti-PD-1, anti-PD-1/4-1BB combined, or by anti-CD4 treatment, but not by anti-CTLA-4 or anti-4-1BB monotherapy. Increased CD8+ T cell effector function and TCR diversity with enrichment of certain TCR clonotypes in the tumor was associated with anti-tumor effects. In contrast, polyclonal activation of T-cells in the periphery was associated with tissue damage. Thus, optimal combination therapy increases TCR diversity with extended activation of selective CD8+ T-cells specifically in the tumor but not in the periphery. Incorporation of the concept of evenness for the TCR diversity is proposed.

SUBMITTER: Hosoi A 

PROVIDER: S-EPMC5773695 | biostudies-other | 2018 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.

Hosoi Akihiro A   Takeda Kazuyoshi K   Nagaoka Koji K   Iino Tamaki T   Matsushita Hirokazu H   Ueha Satoshi S   Aoki Shin S   Matsushima Kouji K   Kubo Masato M   Morikawa Teppei T   Kitaura Kazutaka K   Suzuki Ryuji R   Kakimi Kazuhiro K  

Scientific reports 20180118 1


To facilitate the optimization of cancer immunotherapy lacking immune-related adverse events, we performed TCR repertoire analysis of tumor-infiltrating CD8<sup>+</sup> T-cells in B16 melanoma-bearing mice receiving anti-PD-1, anti-CTLA-4, anti-4-1BB, anti-CD4 or a combination of anti-PD-1 and 4-1BB antibodies. Although CD8<sup>+</sup> T-cells in the tumor were activated and expanded to a greater or lesser extent by these therapies, tumor growth suppression was achieved only by anti-PD-1, anti-P  ...[more]

Similar Datasets

| S-EPMC5143474 | biostudies-literature
| S-EPMC5292650 | biostudies-literature
| S-EPMC5680273 | biostudies-literature
| S-EPMC8183670 | biostudies-literature
| S-EPMC4774199 | biostudies-literature
| S-EPMC8115550 | biostudies-literature
| S-EPMC7998134 | biostudies-literature
| S-EPMC10475737 | biostudies-literature
| S-EPMC7573510 | biostudies-literature
| S-EPMC8027170 | biostudies-literature